Literature DB >> 31023861

Clinical Characteristics and Survival of Patients with Malignant Ovarian Tumors in Addis Ababa, Ethiopia.

Swantje Piszczan1, Dawit Desalegn2, Hezkiel Petros2, Mengistu Gurmu2, Eric Sven Kroeber3, Adamu Addissie4, Rafael Mikolajczyk3, Rahel G Ghebre5, Assefa Mathewos4, Christoph Thomssen1, Ahmedin Jemal6, Eva Johanna Kantelhardt7.   

Abstract

BACKGROUND: Ovarian cancer is the third leading cause of cancer death among women in Ethiopia, with about 2,550 diagnosed cases and 2,000 deaths each year. The incidence and mortality rates of this disease have been increasing in Ethiopia and other parts of sub-Saharan Africa over the past decades because of changing lifestyle and reproductive factors. In this study, we describe the clinical characteristics, treatment patterns, and survival of patients with ovarian cancer in Ethiopia.
MATERIALS AND METHODS: This retrospective cohort study included 485 patients diagnosed between January 2009 and October 2015 at Addis Ababa University Hospital, Zewditu Memorial Hospital, or registered in the Addis Ababa population-based cancer registry. Follow-up data were obtained via telephone. Primary endpoint was all-cause mortality.
RESULTS: The median age was 46 years (range, 11-95). The estimated 1- and 2-year overall survival rates were 78% (95% confidence interval [CI] 0.741-0.82.5) and 59% (95% CI, 0.538-0.646), respectively. Of those patients with result available (n = 423), 73.0% had epithelial cancers. Almost half were classified as Federation of Gynecology and Oncology stage III or IV (48.2%; stage available n = 201) resulting in worse outcomes (hazard ratio [HR], 2.91 [CI 0.67-12.64] and 3.03 [0.69-15.79], respectively). Four out of five patients received some form of surgery (82%), three out of five received platinum-containing chemotherapy. Patients with residual tumor after surgery (n = 83) showed worse survival outcome (HR, 2.23; 95% CI 1.08-4.49).
CONCLUSION: Our study revealed substantial treatment gaps with respect to surgery and adequate chemotherapy. Higher stage, residual tumor and lack of chemotherapy impaired the outcome. Access to higher standards of ovarian cancer treatment is urgently needed in Ethiopia. IMPLICATIONS FOR PRACTICE: Ovarian cancer is often a fatal disease in high resource settings; now it is also becoming important in Ethiopia. This study included 485 women with malignant ovarian tumors treated in Addis Ababa who had a mean age of only 46 years because of the young population structure. Three quarters had the typical epithelial cancer, with half presenting with advanced stage III and IV. Improved oncologic surgery and sufficient chemotherapy could possibly improve their outcome. The relatively high proportion of women with nonepithelial cancer need adequate treatment options to have good prognosis. © AlphaMed Press 2019.

Entities:  

Keywords:  Africa; Ethiopia; Ovarian cancer; Ovarian neoplasms; Survival

Mesh:

Year:  2019        PMID: 31023861      PMCID: PMC6656495          DOI: 10.1634/theoncologist.2018-0869

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  24 in total

1.  Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma.

Authors:  Mirjam J A Engelen; Henrike E Kos; Pax H B Willemse; Jan G Aalders; Elisabeth G E de Vries; Michael Schaapveld; Renee Otter; Ate G J van der Zee
Journal:  Cancer       Date:  2006-02-01       Impact factor: 6.860

Review 2.  Palliative care in ovarian carcinoma patients-a personalized approach of a team work: a review.

Authors:  Yakir Segev; Lior Segev; Meirav Schmidt; Ron Auslender; Ofer Lavie
Journal:  Arch Gynecol Obstet       Date:  2017-08-12       Impact factor: 2.344

3.  Recent Trends in Ovarian Cancer Incidence and Relative Survival in the United States by Race/Ethnicity and Histologic Subtypes.

Authors:  Hyo K Park; Julie J Ruterbusch; Michele L Cote
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-07-27       Impact factor: 4.254

4.  Large ovarian cancer screening trial shows modest mortality reduction, but does not justify population-based ovarian cancer screening.

Authors:  Nicolas Wentzensen
Journal:  Evid Based Med       Date:  2016-07-22

5.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.

Authors:  Jacques Ferlay; Hai-Rim Shin; Freddie Bray; David Forman; Colin Mathers; Donald Maxwell Parkin
Journal:  Int J Cancer       Date:  2010-12-15       Impact factor: 7.396

6.  Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO).

Authors:  Andreas du Bois; Alexander Reuss; Eric Pujade-Lauraine; Philipp Harter; Isabelle Ray-Coquard; Jacobus Pfisterer
Journal:  Cancer       Date:  2009-03-15       Impact factor: 6.860

7.  Delays in presentation and management of ovarian cancer in Lagos, Nigeria.

Authors:  K A Rabiu; O I Akinola; A A Adewunmi; A O Fabamwo; M O Adedeji; A O Popoola
Journal:  J Obstet Gynaecol       Date:  2013-04       Impact factor: 1.246

8.  The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2).

Authors:  Melissa Matz; Michel P Coleman; Milena Sant; Maria Dolores Chirlaque; Otto Visser; Martin Gore; Claudia Allemani
Journal:  Gynecol Oncol       Date:  2016-12-06       Impact factor: 5.482

9.  First data from a population based cancer registry in Ethiopia.

Authors:  Genebo Timotewos; Asmare Solomon; Assefa Mathewos; Adamu Addissie; Solomon Bogale; Tigeneh Wondemagegnehu; Abraha Aynalem; Bekele Ayalnesh; Hailemariam Dagnechew; Wondatir Bireda; Eric Sven Kroeber; Rafael Mikolajczyk; Freddie Bray; Ahmedin Jemal; Eva Johanna Kantelhardt
Journal:  Cancer Epidemiol       Date:  2018-02-02       Impact factor: 2.984

10.  Cancer in Africa 2012.

Authors:  D Maxwell Parkin; Freddie Bray; Jacques Ferlay; Ahmedin Jemal
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-04-03       Impact factor: 4.254

View more
  1 in total

1.  Antiproliferative Effects of Alkaloids from the Bulbs of Crinum abyscinicum Hochst. ExA. Rich.

Authors:  Besufekad Abebe; Solomon Tadesse; Ariaya Hymete; Daniel Bisrat
Journal:  Evid Based Complement Alternat Med       Date:  2020-10-31       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.